Powder: -20°C for 3 years | In solvent: -80°C for 1 year
T-2513 is a potent and specific inhibitor of topoisomerase I. It acts by forming covalent bonds with the topoisomerase I-DNA complex, thereby enhancing its stability. This interaction disrupts the normal process of DNA replication and RNA synthesis, ultimately resulting in cellular apoptosis.
产品描述 | T-2513 is a potent and specific inhibitor of topoisomerase I. It acts by forming covalent bonds with the topoisomerase I-DNA complex, thereby enhancing its stability. This interaction disrupts the normal process of DNA replication and RNA synthesis, ultimately resulting in cellular apoptosis. |
体外活性 | SN-38 is the metabolite of T-2513[1]. T-2513 has a broad cytotoxicity against a range of human tumor cell lines[2]. Cell Cytotoxicity Assay[2]Cell Line: WiDr, HT-29, SK-BR-3, MKN-1, SK-LU-1, LX-1, KB, and HeLaS3 cells Concentration: 15.1-111.5 ng/mL Incubation Time: 24 hours Result: Exhibited cytotoxicity against a panel of human tumor cell lines with GI 50 s of 32.1, 97.6, 38.6, 15.6, 111.5, 15.1, 34.0, and 50.9 ng/mL for WiDr, HT-29, SK-BR-3, MKN-1, SK-LU-1, LX-1, KB, and HeLaS3 cells, respectively. |
体内活性 | T-2513 (1-100 mg/kg) shows Antitumor Activity against Walker-256 carcinoma[2]. Animal Model: Rats bearing Walker-256 carcinoma[2]Dosage: 1, 10, and 100 mg/kg Administration: Result: The ED 50 was 23 mg/kg. |
分子量 | 449.507 |
分子式 | C25H27N3O5 |
CAS No. | 288247-87-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
T-2513 288247-87-0 T2513 T 2513 Inhibitor inhibitor inhibit